Loading stock data…
TRVI
$14.26-0.40 (-2.73%)
After Hours$14.26+0.00 (+0.00%)· Last close May 6
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Trevi Therapeutics, Inc. in the Healthcare sector is trading at $14.27. The stock is currently near its 52-week high of $16.12, remaining 32.1% above its 200-day moving average. Technical signals show neutral RSI of 47 and bearish MACD signal, explaining why TRVI maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 47) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$14.26
Potential Upside
5%
Whystock Fair Value$14.97
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus11 analysts
Mean target$22.09+54.9%
Range$16.00 – $27.00
Fundamentals
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.10B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
1.00
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-17.55%
Volume
Today's trading volume
1.71M
Recent News
Trevi Therapeutics, Inc. Q1 2026 Earnings Call Summary
Moby summary of Trevi Therapeutics, Inc.'s Q1 2026 earnings call
Why Trevi Therapeutics (TRVI) Is Up 5.9% After Extending Its Cash Runway Into 2030
Trevi Therapeutics recently reported a first‑quarter 2026 net loss of US$13.19 million, broadly flat on a per‑share basis, while outlining plans to advance multiple chronic cough trials for its lead drug Haduvio. Alongside this, the company raised approximately US$162 million in a follow‑on offering, extending its cash runway into 2030 and supporting expanded clinical development and intellectual property efforts. We’ll now examine how the extended cash runway to 2030 reshapes Trevi’s...
Trevi Therapeutics Q1 Earnings Call Highlights
Trevi Therapeutics (NASDAQ:TRVI) management used the company’s first-quarter 2026 earnings call to outline upcoming clinical milestones for its chronic cough programs and to highlight an expanded cash runway following an April equity offering. Clinical program updates and upcoming trial starts Pres
Did Trevi’s US$173 Million Raise and Share Expansion Just Reshape Trevi Therapeutics' (TRVI) Investment Narrative?
Trevi Therapeutics recently closed an underwritten public offering of 13,340,000 common shares, raising approximately US$173 million before fees, and separately proposed doubling its authorized common stock to 400,000,000 shares via an amendment to its Delaware certificate of incorporation. The combination of a sizeable capital raise and a request for significantly more authorized shares gives Trevi added financial flexibility for future financing, partnering or incentive programs without...
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday as Investors Take Positions Amid Corporate Earnings
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.3% and the actively trad